The quality-of-life burden of knee osteoarthritis in New Zealand adults: A model-based evaluation

Abstract

BackgroundKnee osteoarthritis is a leading global cause of health-related quality of life loss. The aim of this project was to quantify health losses arising from knee osteoarthritis in New Zealand (NZ) in terms of quality-adjusted life years (QALYs) lost.MethodsThe Osteoarthritis Policy Model (OAPol), a validated Monte Carlo computer simulation model, was used to estimate QALYs lost due to knee osteoarthritis in the NZ adult population aged 40–84 over their lifetimes from the base year of 2006 until death. Data were from the NZ Health Survey, NZ Burden of Diseases, NZ Census, and relevant literature. QALYs were derived from NZ EQ-5D value set 2. Sensitivity to health state valuation, disease and pain prevalence were assessed in secondary analyses.ResultsBased on NZ EQ-5D health state valuations, mean health losses due to knee osteoarthritis over people’s lifetimes in NZ are 3.44 QALYs per person, corresponding to 467,240 QALYs across the adult population. Average estimated per person QALY losses are higher for non-Māori females (3.55) than Māori females (3.38), and higher for non-Māori males (3.34) than Māori males (2.60). The proportion of QALYs lost out of the total quality-adjusted life expectancy for those without knee osteoarthritis is similar across all subgroups, ranging from 20 to 23 percent.ConclusionsAt both the individual and population levels, knee osteoarthritis is responsible for large lifetime QALY losses. QALY losses are higher for females than males due to greater prevalence of knee osteoarthritis and higher life expectancy, and lower for Māori than non-Māori due to lower life expectancy. Large health gains are potentially realisable from public health and policy measures aimed at decreasing incidence, progression, pain, and disability of osteoarthritis.

Umbilical Cord-Derived Mesenchymal Stromal Cells (MSCs) for Knee Osteoarthritis: Repeated MSC Dosing Is Superior to a Single MSC Dose and to Hyaluronic Acid in a Controlled Randomized Phase I/II Trial

“…Osteoarthritis (OA) is the most common joint disease, leading to chronic pain, poor quality of life, and increased mortality . This imposes a major social burden due to elevated health care costs and premature workforce retirement .…”

Denosumab Treatment Improved Health‐Related Quality of Life in Osteoporosis: A Prospective Cohort Study

“…We further identified that improvement in HRQOL with denosumab treatment was negatively impacted by the presence of knee osteoarthritis and multiple comorbidities. Previous studies reported a decrease in HRQOL among patients with knee osteoarthritis . Other studies have identified previous spinal fractures and comorbidities as factors associated with low health utility .…”

“…JBMR Plus (WOA) patients with knee osteoarthritis. (35,36) Other studies have identified previous spinal fractures and comorbidities as factors associated with low health utility. (37,38) Guillemin et al (38) showed that a higher number of comorbidities was associated with a reduced HRQOL.…”

Increasing range of motion in total knee replacement using novel patellar resection technique

“…1 Knee osteoarthritis is associated with huge economic costs and reduced quality of life. 2 Total knee arthroplasty (TKA), a surgical procedure, is designed to improve functions and alleviate pain in patients suffering from knee osteoarthritis or rheumatoid arthritis. 3 However, functional performance after TKA is lower as compared to healthy adults.…”